Phase 3 Readout
UTHR: Phase 3 Topline: A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refra
June 1, 2026 · regorafenib. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2026
- Company
- UNITED THERAPEUTICS Corp (UTHR)
- Drug
- regorafenib
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refra
- Drug
- regorafenib
- Indication
- Gastro-Oesophageal Cancer
Other upcoming events for UTHR
Phase 3 ReadoutPhase 3 Topline: Opiate-sparing Post-operative Pain Control in Septorhinoplasty: A Prospective Randomized, Double Bli
Phase 2 StartPhase 2 Start: Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Momelo
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepa